ConferenceAnn Surg Oncol · February 2026
BACKGROUND: Veterans Affairs (VA) patients participate within the largest USA equal-access healthcare system, though still experience cancer mortality disparities by social determinants. The Social Vulnerability Index (SVI)-measuring community poverty, min ...
Full textLink to itemCite
ConferenceCancer · January 1, 2025
BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a cutaneous sarcoma with an infiltrative growth pattern that makes it challenging to clear margins. High quality data regarding DFSP natural history, management, and outcomes are limited. METHODS: Data ...
Full textLink to itemCite
ConferenceCancer Research · September 15, 2024
AbstractEven in its localized stages, pancreatic ductal adenocarcinoma (PDAC) is virtually incurable, characterized by early dissemination and disease recurrence. The liver is the most common site of metasta ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2024
2668Background: Peritoneal surface malignancies (PSM) constitute a group of difficult-to-treat metastatic diseases that respond poorly to standard chemotherapy. Talimogene Laherparepvec (T-VEC), the first FDA-approved oncolytic virus (OV), demonstrates pot ...
Full textCite
ConferenceCancer Research · January 16, 2024
AbstractEven in its earliest stages, pancreatic ductal adenocarcinoma (PDAC) is an essentially incurable disease due to the presence of disseminated, yet radiographically occult cancer cells in the setting o ...
Full textCite
ConferenceBritish Journal of Surgery · June 9, 2023
AbstractBackgroundMultimodal therapy for localized rectal cancer (RC), including (neo-)adjuvant systemic therapy and surgery, has impr ...
Full textCite
ConferenceJ Surg Oncol · March 2020
BACKGROUND: Chemotherapy improves outcomes in patients with resectable gastric cancer. Minimally invasive gastrectomy (MIS) rates are increasing, though the impact of MIS on postoperative chemotherapy remains uncertain. This study examines the impact of MI ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · March 2020
BACKGROUND: Esophageal neuroendocrine tumors (eNETs) are exceedingly rare, aggressive and have a poor prognosis. Treatment guidelines are ill-defined and mainly based on evidence from case reports and analogous experiences drawn from similar disease sites. ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · October 20, 2018
108 Background: To assess quality in breast cancer care, standardized metrics are needed. Many accepted breast performance metrics are based on evidence-based practice; however, most fail to reflect patient choice in treatment de ...
Full textCite
ConferenceJ Surg Oncol · August 2017
BACKGROUND: Neoadjuvant therapy has theoretical benefits for pancreatic cancer; however, its association with perioperative outcomes remains controversial. This study sought to evaluate variation in use of neoadjuvant therapy and outcomes following pancrea ...
Full textLink to itemCite
ConferenceAnn Surg · August 2017
OBJECTIVE: This study compares outcomes following pancreaticoduodenectomy (PD) for patients treated at local, low-volume centers and those traveling to high-volume centers. BACKGROUND: Although outcomes for PD are superior at high-volume institutions, not ...
Full textLink to itemCite
ConferenceAnn Surg Oncol · March 2016
BACKGROUND: The modifiable variable best proven to improve survival after resection of pancreatic adenocarcinoma is the addition of adjuvant chemotherapy. A theoretical advantage of minimally invasive pancreaticoduodenectomy (MI-PD) is the potential for gr ...
Full textLink to itemCite
ConferenceCancer Research · August 1, 2015
AbstractIntra-operative detection of residual cancer in the tumor bed can be used to decrease the risk of a positive surgical margin, reduce the rate of re-excision, and tailor adjuvant therapy. LUM015 is a ...
Full textCite
ConferenceAnn Surg Oncol · November 2014
BACKGROUND: The purpose of this study was to define the learning curves for laparoscopic pancreaticoduodenectomy (LPD) with and without laparoscopic reconstruction, using paired surgical teams consisting of advanced laparoscopic-trained surgeons and advanc ...
Full textLink to itemCite
ConferenceJ Am Coll Surg · September 2014
BACKGROUND: Patients with advanced gastrointestinal stromal tumors (GIST) are at high risk for recurrence after surgery. The aim of this study was to characterize outcomes of advanced GIST treated with surgery from a large multi-institutional database in t ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · January 20, 2014
85 Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the GI tract. Overall surgical experience with minimally invasive surgery (MIS) has increased, however, published reports on MIS rese ...
Full textCite
ConferenceJournal of Clinical Oncology · February 1, 2011
418 Background: Appendiceal carcinomas are rare neoplasms that often present as peritoneal surface malignancies. The tumors are treated similarly to primary colorectal metastases, despite having different biological environments. ...
Full textCite
